Search results
Is CRISPR Therapeutics Stock a Buy?
Motley Fool via Yahoo Finance· 4 days agoThe company made tremendous progress over the past few years, culminating in its first regulatory approval -- for Casgevy, a therapy for the rare blood...
Attention Biotech Investors - Stocks To Watch From RBC Global Healthcare Conference - Agios...
Benzinga· 5 days agoAt the RBC Global Healthcare Conference, held on 14-15 May, RBC’s Healthcare Desk Sector Strategist...
Top Stock Reports for UnitedHealth, Danaher & Abbott
Zacks via Yahoo Finance· 20 hours agoToday's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Danaher Corporation (DHR) and...
BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?
TipRanks via Yahoo Finance· 4 days agoLast week, Bluebird Bio (NASDAQ:BLUE) shares climbed while CRISPR Therapeutics (NASDAQ:CRSP) stock...
Sickle cell anemia treatment: Medications and more
Medical News Today· 6 days agoSickle cell anemia is the most severe form of sickle cell disease (SCD). Treatments for sickle cell anemia include medications, blood transfusions, and...
Is Excess Iron Becoming a Silent Epidemic?
Mercola· 2 days agoIn this interview, Christy Sutton, D.C., reviews the dangers of excessive iron. While most doctors look for iron deficiency, few ever pay attention to elevated iron. Without sufficient iron, ...
The price of hope: CAR-T therapy in pediatric leukemia
Medical Xpress· 20 hours agoWe stand at the crossroads of medical innovation, where cutting-edge scientific discoveries...
PTAB Issues Final Written Decisions On Zynteglo® Gene Therapy Patents | JD Supra
JD Supra· 1 day agoIn its FWDs the PTAB found that the challenged claims of Sloan Kettering Institute for Cancer Research (“Sloan Kettering”) U.S. Pat. No. 7,541...
Is Bluebird Bio Stock a Buy?
Motley Fool via Yahoo Finance· 5 days agoWhat makes it the most important? The number of potential patients. Zynteglo, which targets another rare blood disease called transfusion-dependent beta-...
How Gene Editing Therapies Could Go Beyond Rare Diseases
Forbes· 5 days agoEarlier this year, a group of scientists in the Netherlands used the gene editing tool CRISPR to...
